FDA Grants Final Approval for OMCAZIO™ (cabozantinib) Capsules, Offering Flexible Dosing for Cancer Patients

The U.S. Food and Drug Administration (FDA) has granted final approval to Handa Oncology's OMCAZIO™ (cabozantinib) capsules. This formulation allows the cancer drug to be administered with or without food, providing greater flexibility for adult patients with advanced renal cell carcinoma, hepatocellular carcinoma, and neuroendocrine tumors.